FGFR2-Altered Cholangiocarcinoma: FDA Approves Lirafugratinib: US FDA | September 2026

What’s New?

The FDA has approved lirafugratinib (Lyrfigtu) for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement.

• Approval was supported by the multicenter REFOCUS study.
• Among 116 FGFR-inhibitor–naïve patients, the confirmed objective response rate was 46%.
• Median duration of response was 11.8 months.
• The supporting efficacy dataset was single-arm, without a randomized comparator.
• Important toxicities include ocular toxicity, hyperphosphatemia and soft-tissue mineralization.
• Comparative efficacy against other available FGFR inhibitors remains unknown.

Why Does It Matter?

The expanding number of genotype-directed therapies makes molecular characterization increasingly central to advanced biliary-tract cancer management. Identifying an actionable FGFR2 alteration can directly determine later-line treatment options.

GastroAGI Takeaway

Test early, because molecular results increasingly determine treatment. Lirafugratinib provides another targeted option for previously treated FGFR2-rearranged advanced cholangiocarcinoma and further strengthens the case for comprehensive molecular profiling early in the disease course. The 46% response rate is clinically meaningful, but the single-arm evidence does not establish superiority over other FGFR inhibitors.